Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering Vanceril phase-out

Executive Summary

Schering-Plough completely discontinues Vanceril with phase-out of 42 mcg strength, company says. Vanceril (beclomethasone) 84 mcg was previously discontinued as part of Schering's consent decree with FDA (1"The Pink Sheet" May 27, p. 13). The lower strength of the asthma drug had been on back-order for some time, Schering said. Vanceril generated $82 mil. in sales in 2001...

You may also be interested in...

Qvar Sales Reps Grow To 200; Ivax Sees Outlicensing Opportunities From R&D

Ivax will have 200 sales reps to promote Qvar and its other respiratory products by the end of the year, President Neil Flanzraich said in Ivax's third quarter conference call Oct. 29

Schering Rebetol Is Only “Medically Necessary” Oral Product In FDA Decree

Schering-Plough's Rebetol (ribavirin capsules) is the only oral product deemed "medically necessary" under the company's consent decree with FDA

USP Nitrosamine Impurities Chapter Reflects Careful Coordination With US, EU Authorities

The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts